RxDoctor Payments Data

Jason Kehrer, DO

Radiation Oncology · Reno, NVNPI 1710114616

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,281 of the $26,719 with a category attached, or 68.4%. Teleflex LLC accounts for 68.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $18,908 and has fallen 97.1% since, to $557 in 2025. Among radiation oncology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,719in general payments, 2019–2025

Across 82 payments — averaging $325.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$18K
  • Palette Life Sciences, Inc.$7K
  • Myriad Genetic Laboratories, Inc.$318
  • AbbVie$176
  • Telix Pharmaceuticals$173
  • Boston Scientific$124
  • plus $931 from 12 others

What the payments were for

  • Consulting fees$4,05015%
  • Speaking & faculty fees$18,28168%
  • Travel & lodging$2,1068%
  • Food & beverage$2,2819%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,719 in reported general payments places this provider in the 90th percentile of 47 radiation oncology providers in Nevada.

See all radiation oncology providers in Nevada

Medicare billing

Part B allowed, 2024
$2,626,385
Medicare patients
361
Services billed
9,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl45$1,035
Ciprofloxacin Hcl12$17

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →